Connect your AI

Solid Biosciences Inc. SLDB Total Assets

Total Assets at other companies

Sarepta Therapeutics, Inc.SRPT

$3.18B-8.3%

BiogenBIIB

$29.48B+5.2%

Neurocrine BiosciencesNBIX

$4.91B+33.0%

InsmedINSM

$2.08B+15.2%

Dyne Therapeutics, Inc.DYN

$1.08B+49.8%

Taysha Gene Therapies, Inc.TSHA

$300.35M+117%

Other financials

Income statement

Revenue$2.0M-40.6%

Operating income-$57.3M-43.1%

Net income-$56.7M-44.4%

EPS (diluted)-$0.52+11.9%

Balance sheet

Cash & equivalents$297.1M+41.1%

Total debt$20.7M-12.5%

Total equity$374.1M+27.1%

Cash flow

Operating cash flow-$47.2M-48.3%

CapEx$165.0K+31.0%

Free cash flow-$47.4M-48.2%

Valuation

Market cap$910.66M+145%

Enterprise value$634.23M+244%

P/S112.5×-10.3×

Profitability

Operating margin-1,315.2%-4,060pp

Net margin-1,062.3%-251,151pp

FCF margin-1,247.7%-9,569pp

Returns & leverage

Return on equity-57.4%+2.2pp

Debt / equity0.1×0.0×

Current ratio13.1×+2.2×

Where this comes from

Reported directly by Solid Biosciences Inc. in its filing.

Tagged under the XBRL concept us-gaap:Assets.

The official record: Solid Biosciences Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Solid Biosciences Inc.'s total assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Solid Biosciences Inc.'s total assets?: Solid Biosciences Inc. (SLDB) reported total assets of $422.89M in Q1 2026.
How has Solid Biosciences Inc.'s total assets changed year-over-year?: Solid Biosciences Inc.'s total assets increased by 23.0% year-over-year, from $343.9M to $422.89M.
What is the long-term trend for Solid Biosciences Inc.'s total assets?: Over 5 years (2020 to 2025), Solid Biosciences Inc.'s total assets has grown at a 6.3% compound annual growth rate (CAGR), from $171.17M to $232.54M.
What does total assets mean?: The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.